Entzündungs-Myofibroblastik-Tumor mit funktionsfähigem Fusionstreiber: ALK Fusion (TPM3-ALK, T...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-IMT-HIGH-RISK-BIOLOGY |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-IMT |
| Quellen | SRC-NCCN-SARCOMA |
Ursprung der Roten Flagge
| Begriffsbestimmung | Inflammatory myofibroblastic tumor with actionable fusion driver: ALK fusion (TPM3-ALK, TPM4-ALK, CLTC-ALK; ~50%), ROS1 fusion (~10%), NTRK fusion (rare), RET fusion (rare), or PDGFRB fusion (rare) — opens targeted-therapy line (crizotinib / lorlatinib for ALK; entrectinib / crizotinib for ROS1; larotrectinib / entrectinib for NTRK; selpercatinib for RET) sparing the patient cytotoxic chemotherapy and aggressive surgery for unresectable disease. |
|---|---|
| Klinische Richtung | Intensivierung |
| Kategorie | high-risk-biology |
Logik auslösen
{
"any_of": [
{
"finding": "BIO-ALK-FUSION",
"value": "positive"
},
{
"finding": "BIO-ALK-REARRANGEMENT",
"value": "positive"
},
{
"finding": "BIO-ROS1-FUSION",
"value": "positive"
},
{
"finding": "BIO-NTRK-FUSION",
"value": "positive"
},
{
"finding": "BIO-RET",
"value": "fusion"
}
],
"type": "biomarker"
}
Anmerkungen
IMT is fusion-driven in ~60–70% of cases; comprehensive genomic profiling at diagnosis is now standard. Crizotinib in ALK-positive IMT (Schöffski et al, Lancet Oncol 2018; ORR ~50%; pediatric COG- ADVL0912) — also active in ROS1+ (entrectinib STARTRK-2). Resistance to crizotinib emerges via secondary ALK kinase mutations — switch to lorlatinib (more potent, CNS-penetrant) or alectinib. NTRK-fusion IMT responds to larotrectinib / entrectinib (NCCN tumor-agnostic). RET- fusion IMT case reports of selpercatinib responses. This RF re-routes algorithm from surgery-first / chemotherapy to fusion-targeted 1L.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.